Adverum Biotechnologies Inc. (Lily)

Company Snapshot

Founded: 2006
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: U.S.
Corporate Address: 100 Cardinal Way Redwood City California 94063 U.S. Tel. +1-(650)-656-9323 www.adverum.com

Company Overview

Adverum Biotechnologies Inc. is a clinical-stage gene therapy company focused on addressing unmet medical needs in ocular and rare diseases. It has developed a technique for creating viral vectors that are engineered for enhanced transfection success. The company has utilized viral vector-engineered technology to develop a pipeline of treatments for acute macular degeneration and diabetic retinopathy for clinical use. It develops gene therapy product candidates proposed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its core capabilities include novel vector discovery, nonclinical and clinical development and pre-commercial planning. Adverum Biotechnologies Inc. has assay development and a current good manufacturing practices (cGMP) quality control, as well as in-house manufacturing expertise, specifically in scalable process development.

Adverum Biotechnologies Inc. (Lily) In Reports

Cell and Gene Therapy Tools and Reagents: Global Markets

BCC Research detailed report on Cell and Gene Therapy Tools and Reagents Market covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW). For market estimates, data has been provided for 2024 as...

Cell and Gene Therapy Tools, and Reagents: Global Markets

BCC Research Market Analyst says global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a CAGR of 10.8%.

Cell and Gene Therapy Tools, and Reagents: Global Markets

The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with CAGR of 10.6% for the period of 2022-2027.

Company's Business Segments

  • Gene Therapy : The company develop treatments for serious ocular and rare diseases, particularly wet age-related macular degeneration (wet AMD), with a focus on single-administration, intravitreal (IVT) therapies.

Applications/End User Industries

  • Healthcare
  • Life Sciences
  • Gene Therapy
AI Sentiment